DexCom, Inc. (NASDAQ:DXCM) EVP Sadie Stern Sells 6,184 Shares

DexCom, Inc. (NASDAQ:DXCM - Get Free Report) EVP Sadie Stern sold 6,184 shares of the business's stock in a transaction that occurred on Tuesday, May 27th. The stock was sold at an average price of $85.11, for a total transaction of $526,320.24. Following the sale, the executive vice president now directly owns 109,621 shares of the company's stock, valued at approximately $9,329,843.31. This trade represents a 5.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

DexCom Stock Up 1.3%

DXCM stock traded up $1.10 during trading hours on Friday, reaching $85.96. 4,257,051 shares of the stock were exchanged, compared to its average volume of 4,370,190. The firm's 50-day moving average is $74.67 and its 200-day moving average is $78.65. The company has a market cap of $33.71 billion, a price-to-earnings ratio of 60.11, a PEG ratio of 2.30 and a beta of 1.43. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. DexCom, Inc. has a 12 month low of $57.52 and a 12 month high of $121.47.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). DexCom had a return on equity of 30.14% and a net margin of 14.29%. The business had revenue of $1.04 billion for the quarter, compared to analyst estimates of $1.02 billion. During the same quarter in the prior year, the company earned $0.32 earnings per share. The company's quarterly revenue was up 12.5% on a year-over-year basis. On average, equities research analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current year.

Hedge Funds Weigh In On DexCom

A number of large investors have recently modified their holdings of the business. Forvis Mazars Wealth Advisors LLC boosted its stake in shares of DexCom by 0.7% during the 4th quarter. Forvis Mazars Wealth Advisors LLC now owns 17,481 shares of the medical device company's stock worth $1,359,000 after buying an additional 118 shares during the last quarter. Horizon Investments LLC boosted its stake in shares of DexCom by 2.2% during the 1st quarter. Horizon Investments LLC now owns 5,608 shares of the medical device company's stock worth $383,000 after buying an additional 123 shares during the last quarter. Principal Securities Inc. boosted its stake in shares of DexCom by 3.4% during the 4th quarter. Principal Securities Inc. now owns 4,069 shares of the medical device company's stock worth $316,000 after buying an additional 135 shares during the last quarter. Larson Financial Group LLC boosted its stake in shares of DexCom by 40.5% during the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock worth $37,000 after buying an additional 137 shares during the last quarter. Finally, Nia Impact Advisors LLC boosted its stake in shares of DexCom by 1.4% during the 4th quarter. Nia Impact Advisors LLC now owns 9,850 shares of the medical device company's stock worth $766,000 after buying an additional 140 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

DXCM has been the subject of a number of recent research reports. Piper Sandler dropped their price target on shares of DexCom from $100.00 to $90.00 and set an "overweight" rating for the company in a research note on Friday, May 2nd. The Goldman Sachs Group initiated coverage on shares of DexCom in a research note on Friday. They issued a "buy" rating and a $104.00 target price for the company. Barclays increased their target price on shares of DexCom from $90.00 to $93.00 and gave the stock an "equal weight" rating in a report on Monday, May 5th. Citigroup reissued a "buy" rating and issued a $102.00 price target (up previously from $82.00) on shares of DexCom in a report on Thursday, May 22nd. Finally, Redburn Atlantic upgraded shares of DexCom from a "neutral" rating to a "buy" rating and upped their price objective for the company from $85.00 to $115.00 in a research report on Monday, February 3rd. Five investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, DexCom currently has an average rating of "Moderate Buy" and an average target price of $98.32.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.